



Please check the availability of FLOWer[®] in your region and get more information by visiting our website: www.aorticlab.com The new frontier of EPD to provide higher protection from adverse events during TAVI procedures





AorticLab srl Via Ribes, 5, 10010 Colleretto Giacosa TO, Italy

www.aorticlab.com info@aorticlab.ch



Distributor:





្រាំ Engagement Made Easy:

The distal structure of FLOWer[®] is designed for effortless engagement, ensuring a secure and reliable fit with the aorta.

Efficient Deployment and Intuitive Control:

Adding at most 3 mins to deployment.

] 12 Fr Introducer Compatibility:


Effortless Closure Management compatible with standard, pre-mounted suture-based closure devices.

****** One Design, 3 Sizes:

The different sizes guarantee a perfect fit with aortas ranging from 25 mm to 39 mm. The correct device size is determined during the pre-procedural CT scan analysis.

SIZE	NOMINAL SIZE (mm)	EXPANSION RANGE (mm) (D1)
FLOWer [®] 28	28	≥ 25 TO 29 (included)
FLOWer [®] 32	32	> 29 TO 34 (included)
FLOWer [®] 36	36	> 34 TO 39 (included)







- Minimal to no interference with existing TAVI delivery systems.
- ->> No need for device-specific ACT adjustments.
- Sentle on the vascular access site reducing complications and ensuring a smoother recovery.
- A Minimal thrombogenicity.
- Enhanced tactile sensitivity throughout the deployment process facilitating real-time adjustments for precise and secure positioning.
- **Stability during deployment** with adjustable distal structure and adaptive spine.
- No need for a further access site thanks to the customized pigtail provided with the device.
- Non-traumatic against the aortic wall even during the most complex procedures.



Comprehensive Cerebral Protection:

Advanced filtering technology can capture debris greater than 60 μ m, significantly reducing the risk of stroke and cerebral complications.

Beyond the Brain:

Non-cerebral debris capture and removal, protecting the brain and peripheral circulation.

Clinical Efficiency:

- In in vitro studies, simulating human circulation, FLOWer[®] prevented over 99% of microspheres from reaching the brain and captured 74% of them.
- In clinical trials, an average of 420 particles were captured per filter. More than half of these particles were smaller than 150 μm, highlighting FLOWer[®]'s capability to intercept even the smallest of threats.
- No access site vascular complication in the clinical trial of over 75 patients.
- Stroke rate within 72 hours in the Nautilus clinical trial: 1.5%.

FLOWer - The Complete Embolic Protection Device – Nautilus Study, EuroPCR 2023.
FLOWer® Instruction for Use.